CTXR Citius Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTXR

Price (delayed)

$0.5203

Market cap

$14.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.24

Enterprise value

$10.46M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: 21
Relative Profitability: Rel. Profitability: 24

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.

Highlights
The EPS has surged by 61% year-on-year and by 13% since the previous quarter
CTXR's debt has shrunk by 56% QoQ and by 13% YoY
Citius Pharmaceuticals's quick ratio has shrunk by 68% QoQ
The net income is down by 29% since the previous quarter and by 10% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.citiuspharma.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CTXR

CTXR stock price

How has the Citius Pharmaceuticals stock price performed over time
Intraday
-2.07%
1 week
4.94%
1 month
-8.72%
1 year
-69.21%
YTD
-33.04%
QTD
-13.93%

Financial performance

How have Citius Pharmaceuticals's revenue and profit performed over time
Revenue
$5.61M
Gross profit
$4.49M
Operating income
-$58.44M
Net income
-$46.2M
Gross margin
80.1%
Net margin
-823.3%
The operating income has shrunk by 56% QoQ and by 36% YoY
The revenue has grown by 42% from the previous quarter
The gross profit rose by 42% since the previous quarter
The net income is down by 29% since the previous quarter and by 10% year-on-year

Price vs fundamentals

How does CTXR's price correlate with its fundamentals

Growth

What is Citius Pharmaceuticals's growth rate over time

Valuation

What is Citius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.19
P/S
2.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.86
The EPS has surged by 61% year-on-year and by 13% since the previous quarter
The price to book (P/B) is 84% lower than the 5-year quarterly average of 1.2 and 37% lower than the last 4 quarters average of 0.3
Citius Pharmaceuticals's equity has decreased by 23% QoQ
The revenue has grown by 42% from the previous quarter

Efficiency

How efficient is Citius Pharmaceuticals business performance
The ROIC has contracted by 31% from the previous quarter
CTXR's ROE is down by 28% from the previous quarter and by 10% YoY
The company's return on assets fell by 26% QoQ but it rose by 8% YoY
The return on sales is up by 8% since the previous quarter

Dividends

What is CTXR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTXR.

Financial health

How did Citius Pharmaceuticals financials performed over time
Citius Pharmaceuticals's total assets is 109% higher than its total liabilities
Citius Pharmaceuticals's quick ratio has shrunk by 68% QoQ
Citius Pharmaceuticals's current ratio has surged by 57% YoY but it has decreased by 41% QoQ
CTXR's debt is 99% lower than its equity
CTXR's debt has shrunk by 56% QoQ and by 13% YoY
The debt to equity has plunged by 50% from the previous quarter and by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.